{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:49:50Z","timestamp":1761058190122},"reference-count":30,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.vaccine.2004.11.029","type":"journal-article","created":{"date-parts":[[2004,12,15]],"date-time":"2004-12-15T22:22:15Z","timestamp":1103149335000},"page":"2623-2627","source":"Crossref","is-referenced-by-count":15,"title":["Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children"],"prefix":"10.1016","volume":"23","author":[{"given":"Jamie","family":"Findlow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Deane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germie van den","family":"Dobbelsteen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.11.029_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK","volume":"51","author":"Balmer","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2004.11.029_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England; database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2004.11.029_bib3","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries","volume":"361","author":"Jodar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2004.11.029_bib4","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1086\/345763","article-title":"Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults","volume":"186","author":"Campbell","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2004.11.029_bib5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunological response of man to group B meningococcal polysaccharide antigens","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2004.11.029_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2004.11.029_bib7","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.185.11.1929","article-title":"N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis","volume":"185","author":"Pon","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2004.11.029_bib8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/infdis\/175.2.364","article-title":"Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates","volume":"175","author":"Fusco","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2004.11.029_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"H\u00f8iby","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2004.11.029_bib10","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2004.11.029_bib11","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo","volume":"340","author":"Cassio de Moraes","year":"1992","journal-title":"Lancet (Braz)"},{"key":"10.1016\/j.vaccine.2004.11.029_bib12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.11.029_bib13","first-page":"147","article-title":"Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey","volume":"14","author":"H\u00f8iby","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2004.11.029_bib14","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine","volume":"63","author":"Rosenqvist","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.11.029_bib15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.11.029_bib16","series-title":"Proceedings of the Seventh Meeting of the European Monitoring Group for Meningococci","first-page":"55","article-title":"Validating the serum bactericidal assay for group B meningococci for use in clinical trials","author":"Martin","year":"2003"},{"key":"10.1016\/j.vaccine.2004.11.029_bib17","series-title":"Proceedings of the Fourteenth International Pathogenic Neisseria Conference","first-page":"157","article-title":"Inter laboratory comparison of serum bactericidal titres against 44\/76-SL before and after vaccination with the Norwegian MenBvac OMV vaccine","author":"Borrow","year":"2004"},{"key":"10.1016\/j.vaccine.2004.11.029_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0264-410X(95)98264-B","article-title":"Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine","volume":"13","author":"van der Ley","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.11.029_bib19","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 outer membrane proteins","volume":"17","author":"Cartwright","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.11.029_bib20","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","article-title":"Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2\u20133 and 7\u20138 years of age","volume":"18","author":"de Kleijn","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.11.029_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1099\/13500872-142-1-63","article-title":"Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design","volume":"142","author":"Suker","year":"1996","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2004.11.029_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/mpat.1993.1070","article-title":"A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies by a serogroup B outer membrane protein vaccine","volume":"15","author":"Rosenqvist","year":"1993","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2004.11.029_bib23","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0264-410X(00)00047-5","article-title":"Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine","volume":"18","author":"Martin","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.11.029_bib24","series-title":"Proceedings of the O11. Federation of Infection Societies Seventh Conference","article-title":"Non-culture based characterisation of Neisseria meningitidis to guide Public Health interventions and vaccine development","author":"Kaczmarski","year":"2003"},{"key":"10.1016\/j.vaccine.2004.11.029_bib25","unstructured":"Centers for Disease Control. Report of the 2nd International workshop on meningococcal immunology and serology, 17\u201318 June 1992 (Decatur, GA) Atlanta, CDC. 1992."},{"key":"10.1016\/j.vaccine.2004.11.029_bib26","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/IAI.71.4.1650-1655.2003","article-title":"Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine","volume":"71","author":"Vermont","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.11.029_bib27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0264-410X(01)00371-1","article-title":"Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine","volume":"20","author":"de Kleijn","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.11.029_bib28","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/S0264-410X(02)00151-2","article-title":"Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants","volume":"20","author":"Longworth","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.11.029_bib29","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1128\/IAI.64.7.2745-2751.1996","article-title":"Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine","volume":"64","author":"Rouppe van der Voort","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.11.029_bib30","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1128\/IAI.65.12.5184-5190.1997","article-title":"Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine","volume":"65","author":"Rouppe van der Voort","year":"1997","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04008655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04008655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T19:15:58Z","timestamp":1586027758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04008655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":30,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0264410X04008655"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.11.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}